Filing Alert: Finch Therapeutics Chapter 11
Finch Therapeutics Files Chapter 11 in District of Delaware
Update (Mar. 24, 2026): A comprehensive case summary is now available for the Chapter 11 bankruptcy filing of Finch Therapeutics Group, Inc.
Finch Therapeutics Group, Inc. and its debtor affiliates⁽¹⁾, a Boston, MA-based microbiome therapeutics company, filed for Chapter 11 protection on Mar. 22 in the U.S. Bankruptcy Court for the District of Delaware.
The company reports $1 million to $10 million in assets and $0 to $50 thousand in liabilities⁽²⁾. The filing indicates that there will be funds available for distribution to unsecured creditors. The case number is 26-10409.
⁽¹⁾ For a complete list of debtor entities, see the Chapter 11 Debtors table.
⁽²⁾ Debtor affiliate Finch Therapeutics, Inc. reports liabilities of $10 million to $50 million.
Chapter 11 Debtors
Top Unsecured Claims
Key Parties
Counsel:
- Robert A. Weber
Chipman Brown Cicero & Cole, LLP
Email: [email protected]
Bankruptcy Counsel:
- Ropes & Gray LLP
Investment Banker:
- Rock Creek Advisors
Signatories:
- Matthew P. Blischak – Chief Executive Officer
Claims Agent:
- Omni Agent Solutions, Inc.
Equity Security Holders:
- Crestovo Investor LLC – 24.7% Equity Interest
- Symbiosis LLC – 10% Equity Interest
- Great Point Capital LLC – 7.5% Equity Interest
- Other Minority Holders – 57.8% Equity Interest
Bondoro Insights is continuing to monitor this case and will provide further coverage as appropriate.
Stay informed on every Chapter 11 bankruptcy case with liabilities exceeding $10 million. Subscribe for free to have our coverage delivered directly to your inbox, and explore our full archive of past summaries.
Explore Bondoro Insights for live case dockets and comprehensive coverage of material filings from petition to plan confirmation.
